Latest news with #Alzheimer'sDisease
Indian Express
a day ago
- Health
- Indian Express
Saiyaara shows early onset Alzheimer's in 22-year-old: Why this is extremely rare and cannot be generalised
Bollywood's latest film 'Saiyaara', a love story between a 22-year-old girl battling early onset Alzheimer's and an aspiring musician, may have hit the right emotional chords but its depiction of the neurodegenerative brain disorder is far from reality. Neurologists say early onset generally doesn't happen before 40 and definitive symptoms hardly manifest in a patient in their 20s and 30s. 'Alzheimer's Disease in your 20s is an extremely rare disorder, so rare that there may be a handful of cases in the world. Existing medical literature has nothing by way of Alzheimer's in the 20s and shows early onset to be mostly occurring in people in their 40s. A majority of Alzheimer's patients are 65-plus,' says Dr Shivakumar R, head and senior consultant, neurology, Manipal Hospital, Bengaluru. So the film's depiction of early onset of Alzheimer's is far removed from evidence-based science. What is Alzheimer's Disease? It is a neuro-degenerative brain disorder that slowly destroys memory and thinking skills, and finally the ability to carry out even the simplest tasks and body functions. 'It happens because of clustering of a protein called beta-amyloid, which accumulates outside of nerve cells or neurons. Then there are tangles or twisted fibres of a protein called tau, which accumulates inside neurons. These disrupt normal brain function, leading to cell death and brain shrinkage,' says Dr Shivakumar. Almost everyone develops plaques and tangles as they age. But those with Alzheimer's Disease develop much more. One third of all neuro-degenerative conditions happen to be young-age Alzheimer's, according to Dr PN Renjen, senior neurologist at Apollo Hospital, Delhi. What triggers early or young onset Alzheimer's? That happens when you have a strong family history of the disease-causing gene, which means it has affected family members in multiple generations. 'A person can have early onset when they inherit the gene mutations from their parents. People living with Down's syndrome also carry the risk and may manifest Alzheimer's symptoms 10 to 20 years younger than the general population,' says Dr Shivakumar. What are the symptoms of early-onset Alzheimer disease? They tend to be atypical, ranging between headaches, aggressive behaviour, gait abnormalities and difficulty swallowing, not so much memory problems. 'Trouble solving basic problems, such as keeping track of bills, losing track of the date or time of year, repetitive questioning, difficulty finding words, disorientation, mood disorders and behavioural oddities are also potential early signs,' says Dr Renjen. How is early onset Alzheimer's diagnosed? Since doctors generally don't look for Alzheimer's in younger people, an accurate diagnosis may take a long time and appear confusing. 'Symptoms may be incorrectly attributed to stress or mental health conditions. Besides, there could be conflicting diagnoses by different doctors. Also, the disease affects each person differently and symptoms will vary accordingly,' says Dr Renjen. The current diagnosis of early-onset Alzheimer disease depends on finding quite a few signs of mental decline. Then there could be cognitive tests recommended by the neuropsychologist. Tests of blood, urine and spinal fluid are followed by imaging tests such as CT and MRI scans of your brain. 'Now studies are on to identify biomarkers, like proteins or other markers, that can indicate the presence of a disease,' says Dr Renjen. A study published in Neurology suggests that beta-amyloid plaques can start accumulating in the brain as early as the 20s. This accumulation may not immediately cause noticeable symptoms but could indicate an increased risk for later-onset Alzheimer's. How is early-onset Alzheimer disease treated? There is no cure but early detection means the neurologist can suggest medication to slow down disease progression. Diet, exercise, sleep, cardiovascular and diabetes treatments, antioxidants, and cognitive training are supportive therapies. The average life expectancy after early onset diagnosis is around eight to 10 years but this can go up, depending on individual factors and the progression of the disease.
Time of India
4 days ago
- Health
- Time of India
This superfood, also known as "Lion's Mane", can improve brain ailments, including Alzheimer's
In the ongoing quest to tackle a brain-altering disease such as Alzheimer's disease (AD), a new hope might have surfaced in a humble medicinal mushroom known for its cognitive benefits—Hericium Erinaceus, also called the Lion's mane. A recent study sheds light on this mushroom's therapeutic potential, revealing that its polysaccharide-enriched extract may significantly alleviate symptoms of AD and protect nerve cells from apoptosis through mitochondrial pathways. Alzheimer's and its urgent need for alternatives Researchers are continuously finding ways to explore alternatives to counter this deadly brain-altering disease. AD, accounting for over 60% of dementia cases worldwide, is marked by progressive cognitive decline and poor prognosis. If left untreated, it can lead to fatal complications like pulmonary embolism and even infections. The study titled 'The Neuroprotective Properties of Hericium erinaceus in Glutamate-Damaged Differentiated PC12 Cells and an Alzheimer's Disease Mouse Model' shows that one of the key pathological features of AD includes neuronal apoptosis, heavily associated with mitochondrial dysfunction, particularly an overload of intracellular calcium and the production of reactive oxygen species (ROS), leading to cellular and cellular models have become crucial in testing potential interventions. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like An engineer reveals: One simple trick to get internet without a subscription Techno Mag Learn More Undo In this study, researchers used PC12 cells—a type of rat pheochromocytoma cell line known for mimicking neuronal behavior—as well as a mouse model induced with Alzheimer's-like symptoms through d-galactose and aluminum chloride (AlCl₃) administration. Lion's mane: Mushroom with medicinal might Hericium Erinaceus is no stranger to the world of traditional medicine, often used for its antitumor and antioxidant effects. However, its neuroprotective capabilities are increasingly catching scientists' interest. This miracle mushroom is known to stimulate nerve growth factor (NGF) and support cholinergic neuron development. Other benefits of Lion's mane It supports mental health by alleviating symptoms of anxiety and depression It helps to improve sleep and also reduces irritability It fights oxidative stress and protects cells from aging It protects against gastric ulcers and stomach inflammation Key findings In l-glutamate-induced PC12 cell models, HE showed a marked ability to reverse nuclear apoptotic changes. At concentrations of 50 and 100 µg/mL over 24 and 48 hours, HE stimulated the transformation of PC12 cells into neuron-like shapes, similar to the effect of NGF. The treated cells developed axons and polygonal morphology, with an increase in β-tubulin III expression—a key marker of neuronal differentiation. Notably, HE improved cell viability by mitigating mitochondrial damage and reestablishing membrane potential, thereby preventing apoptosis triggered by oxidative stress and calcium overload. The outcomes of this research underscore HE's potential to interfere with denigrative processes underlying Alzheimer's, notably by targeting the mitochondrial-mediated apoptotic pathway. Our scientists have progressed so much that they are now turning to nature's most overlooked resources, such as fungi, for answers to some of the most complex diseases in nature, like Alzheimer's.
Business Upturn
6 days ago
- Health
- Business Upturn
Dementia Associated with Alzheimer's Disease Drug Development Surges with 180+ Companies Pushing New Therapeutic Frontiers
By GlobeNewswire Published on July 17, 2025, 22:00 IST New York, USA, July 17, 2025 (GLOBE NEWSWIRE) — Dementia Associated with Alzheimer's Disease Drug Development Surges with 180+ Companies Pushing New Therapeutic Frontiers | DelveInsight Dementia associated with Alzheimer's disease is a progressive neurodegenerative condition characterized by memory loss, cognitive decline, and impaired daily functioning. The growing aging population worldwide is leading to a rising prevalence of Alzheimer's-related dementia, fueling demand for effective diagnostics and disease-modifying therapies. DelveInsight's 'Dementia Associated with Alzheimer's Disease Pipeline Insight 2025' report provides comprehensive global coverage of pipeline dementia associated with Alzheimer's disease therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the dementia associated with Alzheimer's disease pipeline domain. Key Takeaways from the Dementia Associated with Alzheimer's Disease Pipeline Report DelveInsight's dementia associated with Alzheimer's disease pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline dementia associated with Alzheimer's disease drugs. active players working to develop pipeline dementia associated with Alzheimer's disease drugs. Key dementia associated with Alzheimer's disease companies such as BioVie, Bristol Myers Squibb, Cognition Therapeutics, TrueBinding, KeyMed Biosciences, Alzinova, AriBio Co., Ltd., Cognition Therapeutics, AbbVie Inc., Allyx Therapeutics, Inc., Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., Amylyx Pharmaceuticals Inc. , Merry Life Biomedical Company , Praxis Bioresearch, Alector, Inc., Galimedix, MIRAMOON Pharma, NervGen Pharma, Psy Therapeutics, NW PharmaTech, PerioTrap Pharmaceuticals, ADEL, Inc., TauRx Therapeutics Ltd, Eli Lilly and Company, Suven Life Sciences, AB Science, Neurim Pharmaceuticals, Merck Sharp & Dohme, Novartis, Priavoid, Pharmazz, Partner Therapeutics, UCB Biopharma, Longeveron Inc., and others are evaluating new dementia associated with Alzheimer's disease drugs to improve the treatment landscape. and others are evaluating new dementia associated with Alzheimer's disease drugs to improve the treatment landscape. Promising pipeline dementia associated with Alzheimer's disease therapies, such as Bezisterim KarXT, CT-1812, TB 006, CM383, ALZ 101, AR1001, CT1812, ABBV-916, ALX-001, E2814, VT301, AMX0035, TML-6, PRX-P4-003, ADP037-ABC, GAL-201, MP-010, NVG 300, PSY-02, EMCBD-1, S-636, ADEL-Y07, TRx0237, Remternetug, Masupirdine, Masitinib, Piromelatine, MK-1167, Siponimod, PRI-002, PMZ-1620, Sargramostim, Bepranemab, Lomecel-B, and others, are in different phases of Dementia Associated with Alzheimer's Disease clinical trials. and others, are in different phases of Dementia Associated with Alzheimer's Disease clinical trials. In May 2025, Nuravax Inc. was awarded a USD 3 million grant from the National Institutes of Health (NIH) to support Duvax, the first dual-target Alzheimer's vaccine, in its entry into human clinical trials. was awarded a USD 3 million grant from the National Institutes of Health (NIH) to support Duvax, the first dual-target Alzheimer's vaccine, in its entry into human clinical trials. In February 2025, NKGen Biotech, Inc . announced that the US Food and Drug Administration had granted Fast Track designation for the investigation of troculeucel, ex vivo expanded autologous NK cell therapy, for the treatment of moderate Alzheimer's disease. . announced that the US Food and Drug Administration had granted Fast Track designation for the investigation of troculeucel, ex vivo expanded autologous NK cell therapy, for the treatment of moderate Alzheimer's disease. In February 2025, Swedish pharmaceutical company AlzeCure Pharma secured a Eur 2.5m (USD 2.62m) grant from the EU's European Innovation Council (EIC) to support a Phase IIa trial of NeuroRestore ACD856 for Alzheimer's disease. Swedish pharmaceutical company AlzeCure Pharma secured a Eur 2.5m (USD 2.62m) grant from the EU's European Innovation Council (EIC) to support a Phase IIa trial of NeuroRestore ACD856 for Alzheimer's disease. In April 2025, Biogen announced that the US Food and Drug Administration had granted Fast Track designation to BIIB080 , an investigational antisense oligonucleotide (ASO) therapy targeting tau, for the treatment of Alzheimer's disease. announced that the US Food and Drug Administration had granted Fast Track designation to , an investigational antisense oligonucleotide (ASO) therapy targeting tau, for the treatment of Alzheimer's disease. In March 2025, Longeveron Inc. announced the positive outcome of a Type B meeting with the US Food and Drug Administration, supporting the advancement of laromestrocel (Lomecel-BTM), a proprietary, scalable, allogeneic, investigational cellular therapy, as a potential treatment for Alzheimer's disease. The Company and the FDA reached foundational alignment on the overall study design for a proposed single, pivotal, seamless adaptive Phase II/III clinical trial, including proposed AD patient population, proposed placebo control, laromestrocel (Lomecel-BTM) dose selection and frequency, trial duration, and trial endpoints. To accelerate the pathway to potential approval, the FDA agreed to consider a BLA based on positive interim trial results from the planned single study. announced the positive outcome of a Type B meeting with the US Food and Drug Administration, supporting the advancement of laromestrocel (Lomecel-BTM), a proprietary, scalable, allogeneic, investigational cellular therapy, as a potential treatment for Alzheimer's disease. The Company and the FDA reached foundational alignment on the overall study design for a proposed single, pivotal, seamless adaptive Phase II/III clinical trial, including proposed AD patient population, proposed placebo control, laromestrocel (Lomecel-BTM) dose selection and frequency, trial duration, and trial endpoints. To accelerate the pathway to potential approval, the FDA agreed to consider a BLA based on positive interim trial results from the planned single study. In February 2025, Neuphoria Therapeutics announced that the company was due to receive a USD 15 million milestone payment from Merck, known as MSD outside the United States and Canada. The payment was triggered by the initiation, by Merck, of a Phase II clinical trial to evaluate the safety and efficacy of MK-1167, an α7 nicotinic acetylcholine receptor positive allosteric modulator (PAM), for the treatment of the symptoms of Alzheimer's disease dementia. announced that the company was due to receive a USD 15 million milestone payment from Merck, known as MSD outside the United States and Canada. The payment was triggered by the initiation, by Merck, of a Phase II clinical trial to evaluate the safety and efficacy of MK-1167, an α7 nicotinic acetylcholine receptor positive allosteric modulator (PAM), for the treatment of the symptoms of Alzheimer's disease dementia. In February 2025, NKGen Biotech announced that the US Food and Drug Administration has granted Fast Track designation for the investigation of troculeucel , ex vivo expanded autologous NK cell therapy, for the treatment of moderate Alzheimer's disease. announced that the US Food and Drug Administration has granted Fast Track designation for the investigation of , ex vivo expanded autologous NK cell therapy, for the treatment of moderate Alzheimer's disease. In February 2025, NeuroTherapia, Inc., a clinical-stage company focused on developing oral therapies for neurodegenerative diseases, announced it had received approval for its Phase II clinical trial from the European Medicines Agency (EMA). NTRX-07, the company's lead molecule, will be administered to Alzheimer's disease (AD) participants for 28 days in this double-masked, randomized clinical trial. In addition to monitoring safety, pharmacokinetics, and standard measures of clinical efficacy (ADAS-cog, MMSA, and Trails Making Test), the trial is also designed to give an indication of target engagement by analyzing various biomarkers of neuroinflammation and neuronal function. a clinical-stage company focused on developing oral therapies for neurodegenerative diseases, announced it had received approval for its Phase II clinical trial from the European Medicines Agency (EMA). NTRX-07, the company's lead molecule, will be administered to Alzheimer's disease (AD) participants for 28 days in this double-masked, randomized clinical trial. In addition to monitoring safety, pharmacokinetics, and standard measures of clinical efficacy (ADAS-cog, MMSA, and Trails Making Test), the trial is also designed to give an indication of target engagement by analyzing various biomarkers of neuroinflammation and neuronal function. In January 2025, the US FDA granted Fast Track designation to Posdinemab , a phosphorylated tau-directed monoclonal antibody (mAb) being investigated to treat patients with early Alzheimer's disease. the US FDA granted Fast Track designation to , a phosphorylated tau-directed monoclonal antibody (mAb) being investigated to treat patients with early Alzheimer's disease. In November 2024 , Alector announced results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease (AD). , announced results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease (AD). In October 2024, Hoth Therapeutics, Inc. announced the granting of a US patent for its pioneering Alzheimer's treatment, HT-ALZ. Request a sample and discover the recent advances in dementia associated with Alzheimer's disease drugs @ Dementia Associated with Alzheimer's Disease Pipeline Report The dementia associated with Alzheimer's disease pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage dementia associated with Alzheimer's disease drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the dementia associated with Alzheimer's disease clinical trial landscape. Dementia Associated with Alzheimer's Disease Overview Dementia is a broad term that refers to a marked decline in cognitive abilities that affects a person's daily functioning. Alzheimer's disease (AD) is the most common form of dementia, responsible for at least two-thirds of cases in people aged 65 and older. AD is a progressive neurodegenerative disorder that begins gradually and leads to worsening impairments in behavior and cognitive skills such as memory, understanding, language, attention, reasoning, and judgment. Although Alzheimer's itself is not directly fatal, it greatly increases the risk of other complications that can ultimately result in death. The diagnosis of Alzheimer's-related dementia usually requires a thorough evaluation, including medical history, cognitive assessments, physical and neurological exams, and sometimes brain imaging. Physicians first exclude other possible causes of cognitive decline, like vitamin deficiencies or thyroid issues. Cognitive tests evaluate memory, problem-solving, and language to identify patterns indicative of Alzheimer's. Brain scans, such as MRI or CT, help detect structural changes like brain shrinkage. More advanced diagnostic tools, including PET scans or cerebrospinal fluid tests, can reveal specific biomarkers linked to Alzheimer's, offering stronger confirmation. Currently, there is no cure for Alzheimer's disease since brain cell loss cannot be reversed. However, treatments are available to ease symptoms and enhance the quality of life for patients and their caregivers. Cholinesterase inhibitors are medications that help reduce cognitive symptoms such as memory problems, confusion, and impaired judgment by improving communication between brain cells and slowing symptom progression. The three FDA-approved drugs commonly used for Alzheimer's treatment include donepezil (Aricept) for all stages, and galantamine (Razadyne) and rivastigmine (Exelon) for mild to moderate stages. Find out more about dementia associated with Alzheimer's disease drugs @ Dementia Associated with Alzheimer's Disease Treatment A snapshot of the Pipeline Dementia Associated with Alzheimer's Disease Drugs mentioned in the report: Drugs Company Phase MoA RoA Bezisterim (NE3107) BioVie III NF-kappa B inhibitor; Tumour necrosis factor inhibitor Oral KarXT Bristol Myers Squibb III Muscarinic M1 receptor agonists; Muscarinic M4 receptor agonists; Muscarinic receptor antagonists Oral Buntanetap Annovis Bio III Alpha-synuclein inhibitors; Amyloid beta-protein precursor inhibitors; HD protein inhibitors; Tau protein inhibitors Oral AR1001 AriBio III Type 5 cyclic nucleotide phosphodiesterase inhibitors Oral CT-1812 Cognition Therapeutics II Sigma-2 receptor antagonists Oral TW001 Treeway B.V. II Antioxidants; Free radical scavengers Oral AMX0035 Amylyx Pharmaceuticals II Ammonia scavenger; Histone deacetylase inhibitor; Phosphotransferase inhibitor Oral CM383 KeyMed Biosciences I Amyloid beta-protein inhibitors Intravenous Learn more about the emerging dementia associated with Alzheimer's disease therapies @ Dementia Associated with Alzheimer's Disease Clinical Trials Dementia Associated with Alzheimer's Disease Therapeutics Assessment The dementia associated with Alzheimer's disease pipeline report proffers an integral view of the emerging dementia associated with Alzheimer's disease therapies segmented by stage, product type, molecule type, route of administration, and mechanism of action. Scope of the Dementia Associated with Alzheimer's Disease Pipeline Report Coverage : Global : Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical Oral, Intravenous, Subcutaneous, Parenteral, Topical Therapeutics Assessment By Molecule Type : Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy : Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy Therapeutics Assessment By Mechanism of Action : Adiponectin stimulants, Interleukin 23 inhibitors, Interleukin 6 inhibitors, Mitogen-activated protein kinase 1 inhibitors, Mitogen-activated protein kinase 3 inhibitors, NF-kappa B inhibitors, Tumour necrosis factor inhibitors, Muscarinic M1 receptor agonists, Muscarinic M4 receptor agonists, Muscarinic receptor antagonists, Microfilament protein modulators, Sigma-2 receptor antagonists, Amyloid beta-protein inhibitors, TREM2 protein-stimulants, Type 5 cyclic nucleotide phosphodiesterase inhibitors, Ammonia scavengers, Histone deacetylase inhibitors, Phosphotransferase inhibitors : Adiponectin stimulants, Interleukin 23 inhibitors, Interleukin 6 inhibitors, Mitogen-activated protein kinase 1 inhibitors, Mitogen-activated protein kinase 3 inhibitors, NF-kappa B inhibitors, Tumour necrosis factor inhibitors, Muscarinic M1 receptor agonists, Muscarinic M4 receptor agonists, Muscarinic receptor antagonists, Microfilament protein modulators, Sigma-2 receptor antagonists, Amyloid beta-protein inhibitors, TREM2 protein-stimulants, Type 5 cyclic nucleotide phosphodiesterase inhibitors, Ammonia scavengers, Histone deacetylase inhibitors, Phosphotransferase inhibitors Key Dementia Associated with Alzheimer's Disease Companies : BioVie, Bristol Myers Squibb, Cognition Therapeutics, TrueBinding, KeyMed Biosciences, Alzinova, AriBio Co., Ltd., Cognition Therapeutics, AbbVie Inc., Allyx Therapeutics, Inc., Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., Amylyx Pharmaceuticals Inc., Merry Life Biomedical Company, Praxis Bioresearch, Alector, Inc., Galimedix, MIRAMOON Pharma, NervGen Pharma, Psy Therapeutics, NW PharmaTech, PerioTrap Pharmaceuticals, ADEL, Inc., TauRx Therapeutics Ltd, Eli Lilly and Company, Suven Life Sciences, AB Science, Neurim Pharmaceuticals, Merck Sharp & Dohme, Novartis, Priavoid, Pharmazz, Partner Therapeutics, UCB Biopharma, Longeveron Inc., and others. : BioVie, Bristol Myers Squibb, Cognition Therapeutics, TrueBinding, KeyMed Biosciences, Alzinova, AriBio Co., Ltd., Cognition Therapeutics, AbbVie Inc., Allyx Therapeutics, Inc., Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., Amylyx Pharmaceuticals Inc., Merry Life Biomedical Company, Praxis Bioresearch, Alector, Inc., Galimedix, MIRAMOON Pharma, NervGen Pharma, Psy Therapeutics, NW PharmaTech, PerioTrap Pharmaceuticals, ADEL, Inc., TauRx Therapeutics Ltd, Eli Lilly and Company, Suven Life Sciences, AB Science, Neurim Pharmaceuticals, Merck Sharp & Dohme, Novartis, Priavoid, Pharmazz, Partner Therapeutics, UCB Biopharma, Longeveron Inc., and others. Key Dementia Associated with Alzheimer's Disease Pipeline Therapies: Bezisterim KarXT, CT-1812, TB 006, CM383, ALZ 101, AR1001, CT1812, ABBV-916, ALX-001, E2814, VT301, AMX0035, TML-6, PRX-P4-003, ADP037-ABC, GAL-201, MP-010, NVG 300, PSY-02, EMCBD-1, S-636, ADEL-Y07, TRx0237, Remternetug, Masupirdine, Masitinib, Piromelatine, MK-1167, Siponimod, PRI-002, PMZ-1620, Sargramostim, Bepranemab, Lomecel-B, and others. Dive deep into rich insights for new dementia associated with Alzheimer's disease treatments, visit @ Dementia Associated with Alzheimer's Disease Drugs Table of Contents 1. Dementia Associated with Alzheimer's Disease Pipeline Report Introduction 2. Dementia Associated with Alzheimer's Disease Pipeline Report Executive Summary 3. Dementia Associated with Alzheimer's Disease Pipeline: Overview 4. Analytical Perspective In-depth Commercial Assessment 5. Dementia Associated with Alzheimer's Disease Clinical Trial Therapeutics 6. Dementia Associated with Alzheimer's Disease Pipeline: Late-Stage Products (Pre-registration) 7. Dementia Associated with Alzheimer's Disease Pipeline: Late-Stage Products (Phase III) 8. Dementia Associated with Alzheimer's Disease Pipeline: Mid-Stage Products (Phase II) 9. Dementia Associated with Alzheimer's Disease Pipeline: Early-Stage Products (Phase I) 10. Dementia Associated with Alzheimer's Disease Pipeline Therapeutics Assessment 11. Inactive Products in the Dementia Associated with Alzheimer's Disease Pipeline 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Key Companies 14. Key Products in the Dementia Associated with Alzheimer's Disease Pipeline 15. Unmet Needs 16. Market Drivers and Barriers 17. Future Perspectives and Conclusion 18. Analyst Views 19. Appendix For further information on the dementia associated with Alzheimer's disease pipeline therapeutics, reach out @ Dementia Associated with Alzheimer's Disease Therapeutics Related Reports Alzheimer's Disease Epidemiology Alzheimer's Disease Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted Alzheimer's disease epidemiology in the 7MM, i.e., the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan. Alzheimer's Disease Market Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Alzheimer's disease companies, including BioVie, AB Science, Cassava Sciences, TauRx Therapeutics, Novo Nordisk, KeifeRx, Eli Lilly, AriBio, Cerecin, Alzheon, Neurim Pharmaceuticals, Syneos Health, Athira Pharma, Annovis Bio, Anavex Life Sciences, AgeneBio, Eisai, among others. Agitation in Alzheimer's Disease Market Agitation in Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key agitation in Alzheimer's disease companies, including Eli Lilly and Co, BioVie Inc., AB Science SA, Annovis Bio Inc., Cognition Therapeutics Inc., Coya Therapeutics Inc., Actinogen Medical Limited, AC Immune SA, Biogen Inc., Longeveron Inc., among others. Psychosis in Parkinson's and Alzheimer's Disease Market Psychosis in Parkinson's and Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key psychosis in Parkinson's and Alzheimer's disease companies, including Sunovion Pharmaceuticals, Karuna Therapeutics, Vanda Pharmaceuticals, Suven Life Sciences, Enterin, Intra-Cellular Therapies, Merck Sharp & Dohme, among others. Alzheimer's Disease Diagnostic Market Alzheimer's Disease Diagnostic Market Insights, Competitive Landscape and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key Alzheimer's disease diagnostic companies, including F. Hoffmann-La Roche Ltd., General Electric Company, 23andMe, Inc., Lilly, Fujirebio, Siemens Medical Solutions USA, Inc., Diadem srl., Todos Medical, DISCERN™, FUJIFILM Holdings America Corporation, Koninklijke Philips N.V., CANON MEDICAL SYSTEMS EUROPE B.V., Shimzadu Corporation., Laboratory Corporation of America® Holdings, Bruker, Magnetica., IMRIS, Deerfield Imaging, Inc., MR Solutions, Hyperfine, Inc., Neusoft Corporation, among others. DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion. Other Business Pharmaceutical Consulting Services Healthcare Conference Coverage Pipeline Assessment Healthcare Licensing Services Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. Connect with us at LinkedIn Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Yahoo
15-07-2025
- Business
- Yahoo
Eli Lilly (LLY) Secures FDA Label Update for Alzheimer's Disease Treatment
Eli Lilly and Company (NYSE:LLY) is one of Goldman Sachs' top healthcare stock picks. On July 9, the company confirmed the approval by the US Food and Drug Administration of a label update for its once-monthly amyloid-targeting therapy for adults with early symptomatic Alzheimer's disease (AD). A doctor holding a microscope in front of a laboratory sample of healthcare products. The new label significantly reduces the incidence of amyloid-related amyloid-related imaging abnormalities with edema/effusion. The company expects the new label update for Kisunla to enhance the way healthcare professionals evaluate treatment options for parents. 'This update underscores our unwavering commitment to patient safety and the advancement of Alzheimer's disease treatment by potentially mitigating the risk of ARIA-E,' stated Brandy Matthews, MD, FAAN, Lilly's Vice President of Global & US Medical Affairs for Alzheimer's Disease. The FDA has approved a more gradual titration that reduces the incidence of ARIA-E by 41% at 24 weeks and by 35% at 52 weeks compared to the original dosing schedule. It should result in lower rates of ARIA-E without compromising Kisunla's ability to reduce amyloid plaque or Kisunla's once-monthly dosing. Eli Lilly will now offer patients and the care team confidence in the safety of Kisunla in reducing amyloid. Eli Lilly and Company (NYSE:LLY) is a pharmaceutical company that discovers, develops, manufactures, and sells human healthcare products. It specializes in a wide range of therapeutic areas, including diabetes, oncology, immunology, and neuroscience. While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 11 Best Green Energy Penny Stocks to Buy Right Now and 10 Most Popular AI Penny Stocks to Buy According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Korea Herald
14-07-2025
- Business
- Korea Herald
Illimis Therapeutics Closes 58 billion KRW ($42 million) Series B Financing to accelerate CNS and Immune Disease Drug Development via GAIA Platform
SEOUL, South Korea, July 14, 2025 /PRNewswire/ -- The Series B round saw strong participation from both existing and new investors, demonstrating high industry confidence in Illimis Therapeutics' vision and technology. Eight existing investors, including DSC Investment, Woori Venture Partners, Korea Development Bank, Aju IB Investment, Quad Asset Management, Company K Partners, GS Ventures, and Dayli Partners, reaffirmed their commitment. They were joined by ten new investors: LB Investment, TS Investment, Shinhan Venture Investment, S&S Investment, Hana Ventures, Maple Investment Partners, A Ventures, IMM Investment, Schmidt, and Industrial Bank of Korea. The proceeds will be used to accelerate the development of GAIA-based Alzheimer's Disease therapeutics, expand its target indications to various immune disorders, and broaden its pipeline of potential blockbuster drug candidates. The company is actively pursuing early-stage collaborations with global pharmaceutical companies and research institutions to add value to internal programs. "In the evolving landscape of new drug development where the limitations of existing medications are continually being overcome, Illimis' differentiated platform technology is expected to emerge as a next-generation treatment option for neuro-immune diseases with high unmet medical needs," said Yohan Kim, Senior Managing Director at DSC Investment, who led this investment round and has also been appointed to the board of directors. Jiwoong Chun, Managing Director at Woori Venture Partners and an active board member and investor since the company's inception, added, "Illimis is a prime example of a smart Korean biotech unlocking global markets with proprietary innovation and capital efficiency." Illimis has recently been selected for the '2025 Global Joint Research to Defeat Dementia' led by the Ministry of Health and Welfare and the Korean Dementia Research Center, securing KRW 2.2 million ($1.6 million) in funding over three years, further validating its technological capabilities. This initiative aims to develop Alzheimer's therapeutics through global joint research leveraging the GAIA platform, positioning Illimis at the center of international collaboration. Furthermore, in October 2024, Illimis partnered with Eli Lilly and Company (Lilly)'s Catalyze360-ExploR&D, a core pillar of external innovation at Lilly dedicated to deploying world-leading research and development capabilities and scientific know-how to accelerate partner science. Under this research collaboration, Illimis and Lilly have been cooperating to advance the platform construct for applications in neurodegenerative diseases. Illimis has also strengthened its global pharma collaborations by winning the 2023 BMS Innovation Square Challenge and joining Johnson & Johnson's global incubator network as a member company of JLABS Singapore in 2024. To further enhance its drug development competitiveness, Illimis Therapeutics operates a Scientific Advisory Board (SAB). The SAB includes Dr. Greg Lemke, Emeritus Professor at the Salk Institute and a world-renowned expert in TAM Biology, and Dr. Morgan Sheng, a leading neuroscientist at the Broad Institute who previously served as Vice President of Neuroscience at Genentech. These experts provide strategic guidance across the entire R&D lifecycle, including pipeline development, candidate discovery, clinical trial design, etc., and play a pivotal role in strengthening Illimis Therapeutics' global partnerships. "This investment, government grants, and partnership with Lilly will enable us to accelerate our efforts to conquer diseases with high unmet clinical needs based on a comprehensive understanding of TAM biology and establish global leadership in TAM biology," said Sanghoon Park, CEO of Illimis Therapeutics. "We will continue to focus on innovative new drug development centered around the GAIA platform and provide tangible treatment options to patients worldwide through early R&D collaboration models." About Illimis Therapeutics Illimis Therapeutics is a pioneering biotechnology company at the forefront of developing innovative therapies for challenging central nervous system (CNS) and immune-related diseases. The company's core strength lies in its proprietary GAIA (Gas6-mediated Anti-Inflammatory Adaptor) platform. This cutting-edge platform is designed to harness the therapeutic potential of TAM (Tyro3, Axl, Mer) receptor biology, a critical pathway involved in regulating inflammation and immune responses. The company's lead pipeline, ILM01 for the treatment of Alzheimer's Disease, is entering into the preclinical stage in the second half of 2025 and expecting to submit an IND by the end of 2027. For more information, visit
